Heart Imaging in Children With Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01633242|
Recruitment Status : Terminated
First Posted : July 4, 2012
Last Update Posted : July 2, 2017
- Muscular dystrophy can affect the muscles used for heart function and breathing. Treatment usually involves drugs that help improve heart function. However, better types of heart imaging studies are needed to improve treatment of heart problems related to muscular dystrophy. Better heart imaging methods are especially needed for children with muscular dystrophy. Researchers want to test different heart imaging methods in children with muscular dystrophy. They will look at cardiac magnetic resonance imaging (MRI) and standard heart function tests.
- To develop and test new methods for imaging the heart in children with muscular dystrophy.
- Children and adolescents between 8 and 17 years of age who have muscular dystrophy.
- Participants will be screened with a physical exam and medical history.
- Participants will provide a blood sample at the start of the study. They will also have heart function tests before having the imaging study.
- Participants will have a cardiac MRI scan that will last up to 60 minutes. Some tests will require a MRI contrast agent (a drug that helps the image appear more clearly on the scan).
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||2 participants|
|Official Title:||A Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy|
|Study Start Date :||February 24, 2012|
|Study Completion Date :||October 11, 2016|
- Evaluate CMR measures in muscular dystrophy patients
- Early Detection
- Measurement of Disease Progression
- Ultimate identification of the response to developing therapies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01633242
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Andrew E Arai, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|